As an adjunctive treatment, empagliflozin improves glycaemic control in patients with HNF1A-related maturity-onset diabetes of the young, a clinical trial shows.
Medscape News UK
Source link : https://www.medscape.com/viewarticle/empagliflozin-benefits-patients-rare-genetic-diabetes-2026a10001to?src=rss
Author :
Publish date : 2026-01-22 12:00:00
Copyright for syndicated content belongs to the linked Source.
